"Obinutuzumab plus bendamustine in rituximab-refractory indolent non-Hodgkin lymphoma" (Click to go to Content)

• Attribution:

  • Sehn LH Chua NS Mayer J, et al. GadoLin: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.

  • https://www.youtube.com/watch?v=WV7ay2HF1zM

    • Chicago ASCO Annual Meeting 2015.

    • Oncoletter: May 30, 2015.

  • Oncoletter Youtube Channel:  https://www.youtube.com/channel/UCScuWa-C47mTYLeGwD5Iqkg

Previous Video

Next Video